Ra Medical Systems, Inc. (RMED) Stock Analysis

Ra Medical Systems, Inc. (RMED) Healthcare & Pipeline Overview

Ra Medical Systems, Inc. develops and markets excimer lasers for treating vascular diseases, focusing on minimally invasive laser ablation technology. Their key product addresses lower extremity vascular blockages, sold primarily through distributors in the United States, positioning them in the competitive medical device landscape.

What Is the Investment Thesis for RMED?

Ra Medical Systems presents a focused investment opportunity within the medical device sector, targeting the treatment of vascular diseases. The company's high gross margin of 92.7% indicates strong pricing power and efficient production. A key value driver is the potential for increased adoption of their laser ablation system as a minimally invasive alternative to traditional surgical methods. The company's current P/E ratio of 0.21 may signal undervaluation relative to its earnings, but warrants careful consideration due to the company's small market capitalization. Growth catalysts include expanding distribution networks and securing additional regulatory approvals for new applications of their laser technology. Potential risks include competition from established medical device companies and the need for ongoing clinical data to support the efficacy and safety of their products.

Based on FMP financials and quantitative analysis

RMED Key Highlights

Gross Margin of 92.7% indicates strong pricing power and efficient production.

• P/E Ratio of 0.21 may signal undervaluation, but requires careful consideration of the company's overall financial health.
• Profit Margin of 5563.4% reflects a potentially unsustainable outlier, requiring further investigation into the specific accounting period.
• Focus on minimally invasive laser ablation technology aligns with the trend towards less invasive surgical procedures.
• Distribution primarily within the United States presents both a focused market and a potential limitation for growth.

Who Are RMED's Competitors?

RMED is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are RMED's Key Strengths?

Proprietary excimer laser technology.

• High gross margin (92.7%).
• Focus on minimally invasive treatment solutions.
• Specialized expertise in vascular disease treatment.

What Are RMED's Weaknesses?

Small market capitalization.

• Limited geographic reach (primarily US).
• Reliance on distributors for sales.
• Dependence on a single product line.

What Could Drive RMED Stock Higher?

Potential regulatory approvals for new applications of their excimer laser technology.

• Continued adoption of their laser ablation system as a minimally invasive alternative.
• Expansion of distribution networks within the United States.
• Publication of clinical data supporting the efficacy and safety of their products.

What Are the Key Risks for RMED?

Financial-distress signal — its Altman Z-Score of -11.93 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Competition from established medical device companies with greater resources.
• Regulatory hurdles and delays in obtaining approvals for new products.
• Product liability claims related to the use of their excimer laser technology.
• Dependence on a single product line, making them vulnerable to market changes.
• Limited financial resources compared to larger competitors.

What Are the Growth Opportunities for RMED?

• Expansion into New Therapeutic Areas: Ra Medical Systems can explore expanding the application of its excimer laser technology to treat other vascular diseases beyond lower extremity blockages. This includes potential applications in coronary artery disease or stroke treatment. The market for cardiovascular devices is estimated at $50 billion annually, providing a substantial opportunity for growth. Timeline: 2-3 years for research and development, followed by clinical trials and regulatory approvals.
• Geographic Expansion: Currently, Ra Medical Systems primarily sells its products in the United States. Expanding into international markets, such as Europe and Asia, could significantly increase its revenue. The European market for medical devices is estimated at $150 billion, while the Asian market is experiencing rapid growth. Timeline: 1-2 years for market research and establishing distribution partnerships, followed by regulatory approvals in each target country.
• Strategic Partnerships: Collaborating with larger medical device companies or healthcare providers could provide Ra Medical Systems with access to broader distribution networks and increased market visibility. Partnerships could also facilitate joint research and development efforts. The value of strategic partnerships in the medical device industry is estimated at $10 billion annually. Timeline: 6-12 months for identifying and negotiating partnerships, followed by implementation of collaborative projects.
• Technological Advancements: Investing in research and development to improve the efficacy and safety of its excimer laser technology could provide Ra Medical Systems with a competitive advantage. This includes developing new catheter designs or refining the laser ablation process. The global market for laser-based medical devices is projected to reach $5 billion by 2028. Timeline: Ongoing research and development efforts, with incremental improvements and new product launches every 1-2 years.
• Direct Sales Model: Transitioning from a distributor-based sales model to a direct sales force could improve Ra Medical Systems' control over its sales process and increase its profit margins. A direct sales force would allow for more targeted marketing efforts and closer relationships with key customers. The cost of establishing a direct sales force is estimated at $1-2 million annually. Timeline: 1-2 years for recruiting and training a sales team, followed by gradual transition from distributor-based sales.

What Are RMED's Competitive Advantages?

• Proprietary excimer laser technology.
• Specialized expertise in laser ablation for vascular disease.
• Established relationships with distributors in the United States.

What Does RMED Do?

Ra Medical Systems, Inc., incorporated in 2002 and headquartered in Carlsbad, California, is a medical device company focused on developing, manufacturing, and marketing excimer lasers for treating vascular and immune-mediated inflammatory diseases. The company's core technology centers around laser radiation ablation, a minimally invasive procedure designed to remove arteriosclerotic blockages. Their primary product is an excimer laser system coupled with single-use catheters, which physicians utilize in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. This system aims to provide a less invasive alternative to traditional surgical methods for patients suffering from peripheral artery disease. Ra Medical Systems distributes its products mainly through a network of distributors within the United States. The company's focus on a specific niche within vascular disease treatment positions it within the broader medical device market, where innovation and minimally invasive techniques are increasingly valued.

What Products and Services Does RMED Offer?

• Develops excimer lasers for medical applications.
• Manufactures excimer laser systems.
• Markets excimer lasers for vascular disease treatment.
• Offers laser radiation ablation technology.
• Provides minimally invasive treatment solutions.
• Focuses on treating arteriosclerotic blockages.
• Sells single-use catheter systems.

How Does RMED Make Money?

• Develops and manufactures excimer laser systems and single-use catheters.
• Sells these systems and catheters to physicians for endovascular treatment.
• Distributes products primarily through distributors in the United States.

What Industry Does RMED Operate In?

Ra Medical Systems operates within the medical device industry, specifically targeting the market for vascular disease treatment. The industry is characterized by technological innovation, stringent regulatory requirements, and intense competition. Market trends favor minimally invasive procedures and advanced technologies like laser ablation. The competitive landscape includes larger, established medical device companies as well as smaller, specialized firms. Ra Medical Systems' focus on excimer laser technology for vascular blockages positions it within a niche segment of this broader market. The global medical device market is projected to reach $600 billion by 2026, driven by an aging population and increasing demand for advanced medical treatments.

Who Are RMED's Key Customers?

• Physicians specializing in endovascular treatment.
• Hospitals and medical centers offering vascular disease treatment.
• Distributors of medical devices in the United States.

Company Profile

Ra Medical Systems, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Carlsbad, US. The company is led by CEO David A. Jenkins. RMED has traded publicly since 2018.

Ra Medical Systems, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -11.93 places it in the distress zone, a signal of elevated financial risk.

Key Financial Metrics

Return on assets is -46.1%, showing how much profit it generates from its asset base. A current ratio of 0.06 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -1.2%, the inverse of the P/E and a quick read on earnings relative to price.

RMED Valuation & Market Position

With a $3.84M market cap, Ra Medical Systems, Inc. sits in the micro-cap segment of the market.

The most recent 10 insider filings for Ra Medical Systems, Inc. break down as 2 sales and 8 purchases. On net that is roughly 122K shares acquired (about $53K) — insiders putting money in tends to read as conviction.

RMED Financials

RMED Latest News

No recent news available for RMED.

RMED Analyst Consensus

RMED MoonshotScore

Common Questions About RMED (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources